This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/johnson-and-johnson-kenvue-ipo-8800eb5f

J&J’s $40 Billion Spinoff Could Rule Consumer Health. But It Has One Rival.

By
Josh Nathan-Kazis
  • Order Reprints
  • Print Article

What’s the combined value of Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, Zyrtec—plus a few more of the biggest names in consumer health? On Monday afternoon, Johnson & Johnson which owns each of these brands, put a number on it: About $40 billion.

That valuation comes as Johnson & Johnson (ticker: JNJ) begins the long-awaited spinoff of its consumer health division under the name Kenvue. The first step is an initial public offering, which could take place in the coming week. Johnson & Johnson is pricing the IPO at between $20 and $23 per share, and expects to raise about $3.2 billion.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.